Cover image of the article: The Difference in Immunoglobulin G Levels Between Outpatients and Inpatients With COVID-19

Image Credit:J Inflamm Dis

The Difference in Immunoglobulin G Levels Between Outpatients and Inpatients With COVID-19

Authors

Parisa Sadat Madani1,*, Monirsadat MirzadehMonirsadat Mirzadeh ORCID1, Saba RostamianSaba Rostamian ORCID1
1Metabolic Diseases Research Center, Research Institute for Prevention of Non-communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.
*Corresponding Author: Metabolic Diseases Research Center, Research Institute for Prevention of Non-communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran. Email: drparisasadatmadani@gmail.com

Journal of Inflammatory Diseases:Vol. 25, issue 3; 191-194
Published online:Dec 31, 2021
Article type:Rapid Communication
How to Cite:Madani PS, Mirzadeh M, Rostamian S. The Difference in Immunoglobulin G Levels Between Outpatients and Inpatients With COVID-19. J Inflamm Dis. 2024;25(3):e156293. doi:

Abstract

Background: Coronavirus disease 2019 (COVID-19) has rapidly become a pandemic since it was first reported in late December 2019. Serological reports are of great value to medical specialists in developing health policies. The detection of Immunoglobulin G (IgG) level in COVID-19 patients can specify a preclinical infection or previous exposure to the virus. Objective: This study aims to assess the IgG rate in patients with COVID-19. Methods: This is a cross-sectional study on 172 patients with confirmed COVID-19 (having positive PCR test) in Qazvin, Iran in 2020, including 86 inpatients and 86 outpatients. In order to measure the IgG levels, the serum samples were collected 3-5 weeks after onset of their clinical symptoms. Data were statistically analyzed in SPSS software v. 20, considering the significance level of P<0.05. Results: Of 172 patients, 81(94.2%) inpatients and 74(86%) outpatients tested positive for IgG, while 5(5.8%) inpatients and 10(11.6%) outpatients tested negative for IgG. The mean IgG level in inpatients was significantly higher than in outpatients (P<0.001) 3-5 weeks after a positive PCR test. Conclusion: The amounts of IgG in the sera of COVID-19 patients 3-5 weeks after the onset of symptoms can help health care authorities develop policies and control strategies by determining the burden of disease, monitoring the spread of disease, and estimating the epidemiological factors.

Highlights

Copyright

© 2024, Journal of Inflammatory Diseases. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

8
Oct
2024
Evaluation of Antibody Response and Reinfection in Improved Hypertensive, Cardiac, and Diabetic Patients with COVID-19 for Six Months in Unvaccinated Outpatients

Evaluation of Antibody Response and Reinfection in Improved Hypertensive, Cardiac, and Diabetic Patients with COVID-19 for Six Months in Unvaccinated Outpatients

Mehdi Fallah Bagher Shaidaei,
Alireza Salmani,
Javad Moazen,
Fatemeh Pourmotahari,
Nooshin Asadmasjedi

Fallah Bagher Shaidaei M, Salmani A, Moazen J, Pourmotahari F, Asadmasjedi N. Evaluation of Antibody Response and Reinfection in Improved Hypertensive, Cardiac, and Diabetic Patients with COVID-19 for Six Months in Unvaccinated Outpatients. J Adv Immunopharmacol. 2024;4(2):e143537. doi: https://doi.org/10.5812/jai-143537

27
Jul
2022
SARS-CoV-2 Antibodies in the Public Hospital Staff: The Second Report of a Seroprevalence Cohort Study from Iran

SARS-CoV-2 Antibodies in the Public Hospital Staff: The Second Report of a Seroprevalence Cohort Study from Iran

Aida Amanat,
Kamran Bagheri Lankarani,
Behnam Honarvar,
Naeimehossadat Asmarian,
Mansoureh Shokripour,
Fatemeh Rafiee
,et al.

Amanat A, Bagheri Lankarani K, Honarvar B, Asmarian N, Shokripour M, et al. SARS-CoV-2 Antibodies in the Public Hospital Staff: The Second Report of a Seroprevalence Cohort Study from Iran. Shiraz E-Med J. 2022;23(9):e121681. doi: https://doi.org/10.5812/semj-121681

23
Aug
2022
Seroprevalence of Anti-SARS-CoV-2 Antibodies in High-Risk Occupational and Low-Risk Groups in Southwestern Iran

Seroprevalence of Anti-SARS-CoV-2 Antibodies in High-Risk Occupational and Low-Risk Groups in Southwestern Iran

Nasrin Aliabadi,
Nahid Heydari Marandi,
Marzieh Jamalidoust,
Zahra Ashkan,
Gholamreza Pouladfar,
Mazyar Ziyaeyan

Aliabadi N, Heydari Marandi N, Jamalidoust M, Ashkan Z, Pouladfar G, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in High-Risk Occupational and Low-Risk Groups in Southwestern Iran. Jundishapur J Microbiol. 2022;15(7):e126975. doi: https://doi.org/10.5812/jjm-126975

18
Jul
2020
Early Intravenous Immunoglobulin as an Effective Drug for the Treatment of COVID-19: A Case Series and Case Review

Early Intravenous Immunoglobulin as an Effective Drug for the Treatment of COVID-19: A Case Series and Case Review

Rozita Khodashahi,
Alireza Sedaghat,
Mandana Khodashahi

Khodashahi R, Sedaghat A, Khodashahi M. Early Intravenous Immunoglobulin as an Effective Drug for the Treatment of COVID-19: A Case Series and Case Review. Arch Clin Infect Dis. 2020;15(5):e103732. doi: https://doi.org/10.5812/archcid.103732

13
Sep
2023
COVID-19 as an Aggravator of Cardiovascular Diseases: Increasing Immunoglobulin G, a Valuable Prognostic Factor for Heart Failure

COVID-19 as an Aggravator of Cardiovascular Diseases: Increasing Immunoglobulin G, a Valuable Prognostic Factor for Heart Failure

Ali Tahan,
Najmaldin Saki,
Shirin Azizidoost,
Farid Yousefi,
Habib Haybar

Tahan A, Saki N, Azizidoost S, Yousefi F, Haybar H. COVID-19 as an Aggravator of Cardiovascular Diseases: Increasing Immunoglobulin G, a Valuable Prognostic Factor for Heart Failure. Jundishapur J Microbiol. 2023;16(8):e139233. doi: https://doi.org/10.5812/jjm-139233

More by these authors

Parisa Sadat MadaniPubMedScholar
Monirsadat MirzadehPubMedScholar
Saba RostamianPubMedScholar
Share
Cited by
Metrics